Beta caryophyllene

Beta-Caryophyllene: A Comprehensive Reference

1. Identity, Nomenclature, and Chemical Characteristics

β-Caryophyllene (BCP), more formally (−)-β-caryophyllene, is a natural bicyclic sesquiterpene that occurs widely in nature. Its systematic IUPAC name is (1R,4E,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene, and its CAS Registry Number is 87-44-5. The molecule carries the molecular formula C₁₅H₂₄ and a molecular weight of 204.35 g/mol. The biologically active, naturally predominant form is the (E)- or trans- isomer, denoted (E)-BCP or trans-β-caryophyllene.

Caryophyllene is notable for having a cyclobutane ring, as well as a trans-double bond in a 9-membered ring, both rarities in nature. Three isomers — α-, β-, and γ-caryophyllene — are found in nature, and the β-isomer is the most frequently encountered and most abundant. β-Caryophyllene is usually found as a mixture with isocaryophyllene (the cis double bond isomer) and α-humulene (obsolete name: α-caryophyllene), a ring-opened isomer.

β-Caryophyllene has a woody-spicy, dry, clove-like aroma. It has traditionally been used to provide a woody, spicy aroma and fragrance to cosmetics and perfumes. Caryophyllene can be produced synthetically, but it is invariably obtained from natural sources because it is widespread.

BCP is described as the first dietary cannabinoid of natural origin, with an abundant presence in a variety of spice blends and citrus flavors, as an additive or preservative, and for aroma in food products and beverages.

2. Natural Sources and Botanical Distribution

BCP is a natural sesquiterpene hydrocarbon present in hundreds of plant species. β-Caryophyllene is widely found in more than 1,000 types of plants, including the essential oils of cinnamon, oregano, black pepper, basil, and cloves. It is a constituent of many essential oils, especially clove oil, the oil from the stems and flowers of Syzygium aromaticum (cloves), the essential oil of Cannabis sativa, copaiba, rosemary, and hops.

A 2020 systematic quantitative analysis published in International Journal of Molecular Sciences provides the most comprehensive botanical inventory to date. A systematic analysis of plant species with essential oils containing a BCP percentage greater than 10% provided almost 300 entries with species belonging to 51 families, and the essential oils were found to be extracted from 13 plant parts, with samples originating from 56 countries worldwide.

Among the richest individual sources documented in the peer-reviewed literature: copaiba balsam (Copaifera officinalis) is among the richest sources (up to 53.3%), followed by black pepper (Piper nigrum) (up to 35%), lemon balm (Melissa officinalis) (up to 19.1%), cloves (Syzygium aromaticum) (up to 12.4%), and hops (Humulus lupulus) (up to 9.8%). In Cannabis sativa, beta-caryophyllene represents a major component of the plant's essential oil composition, with content measurements ranging between 12.5% and 35%.

In copaiba balsam oil, the main component is β-caryophyllene. The copaiba resins are generally composed of a volatile oil made up largely of sesquiterpene hydrocarbons, such as β-caryophyllene, α-copaene, β-elemene, α-humulene, and germacrene D, in addition to several biologically active diterpene acids, including copalic acid, kaurenoic acid, alepterolic acid, and polyalthic acid.

3. Common Forms and Preparations

BCP is encountered commercially and in research in several forms:

• Purified isolated BCP: Extracted from plant essential oils by steam distillation or solvent extraction, then isolated by fractional distillation or chromatography. Available as a neat liquid for use as a flavoring or in supplement capsules and oils.
• Essential oil concentrates: BCP-rich essential oils — particularly copaiba (Copaifera spp.), clove (Syzygium aromaticum), and black pepper (Piper nigrum) — used topically, aromatically, or orally.
• Food additive: β-Caryophyllene is on the list of food additives and flavoring agents approved by the United States Food and Drug Administration (FDA, Code of Federal Regulations No. 21CFR172.515), and studies in animal models have demonstrated a wide variety of pharmacological activities.
• Dietary supplement capsules/soft gels: Oral BCP in carrier oils (typically olive or MCT oil) is commercially available; orally administered BCP is absorbed by the digestive tract and becomes systemically available.
• Topical preparations: Tested concentration ranges in topical research span from 0.5 µM to 10%.
• Cosmetic/fragrance ingredient: β-Caryophyllene has been commonly used as a fragrance chemical since the 1930s.

4. Traditional and Historical Use

While BCP was not historically identified as a discrete compound, the plants most concentrated in BCP have millennia-long medicinal histories across multiple traditional systems. It is important to note that the therapeutic effects attributed to these plants in traditional use were not attributed to BCP specifically, as the compound was not isolated until the 20th century.

4.1 Clove (Syzygium aromaticum)

During the Han dynasty (207 B.C. to 220 A.D.), those who addressed the Chinese emperor were required to hold cloves in their mouths to mask bad breath. Traditional Chinese physicians have long used clove to treat indigestion, diarrhea, hernia, and ringworm, as well as athlete's foot and other fungal infections. India's traditional Ayurvedic healers have used clove since ancient times to treat respiratory and digestive ailments. Clove first arrived in Europe around the 4th century A.D. as a highly coveted luxury, and medieval German herbalists used cloves as part of anti-gout mixtures.

4.2 Copaiba (Copaifera spp.)

The oleoresin of Copaifera trees has been widely used as a traditional medicine in Neotropical regions for thousands of years and remains a popular treatment for a variety of ailments. Copaiba resin oil has been used in folk medicine dating back to the 16th century by the natives of north and northeastern Brazil; their folk remedies were administered orally or used as an ointment in the treatment of various diseases. Spanish explorers documented the use of copaiba resin in the 16th century, bringing it to Europe where it became popular in traditional medicine. The oleoresins of Copaifera have hundreds of pharmacological studies already carried out seeking to confirm and give scientific basis for traditional uses throughout Latin America, especially in the Amazon; copaiba oils are sources of important bioactive molecules, such as beta-caryophyllene, an anti-inflammatory substance for which action on cannabinoid receptors has been recently identified.

4.3 Black Pepper (Piper nigrum) and Other Spices

Black pepper, a significant dietary source of BCP, has been used in Ayurvedic medicine (Trikatu formulations) and traditional Chinese medicine for centuries as a digestive aid, carminative, and in pain-relief formulations. β-Caryophyllene has been described as an ancient remedy to treat pain, found in large amounts in the essential oils of various spice and food plants such as oregano, cinnamon, and black pepper.

4.4 Basil and Lemon Balm

In north Africa, particularly Egypt, basil has been used for centuries for both culinary and medicinal purposes, with archaeological evidence indicating its cultural significance. Historically, basil is used medicinally for gastrointestinal disorders, respiratory ailments, wound care, and general therapeutic purposes within traditional healing systems. The Ayurvedic tradition of the Indian subcontinent represents the most codified and historically documented ethnomedicinal system engaging Ocimum species.

4.5 Scientific Identification

BCP was first isolated in the early 20th century, with significant contributions from chemists studying plant compounds; in 1910 it was identified from clove oil, marking a significant milestone in understanding its chemical structure and properties. The pivotal moment in modern pharmacological understanding came in 2008, when Gertsch and colleagues reported that the widespread plant volatile (E)-β-caryophyllene selectively binds to the CB2 receptor (Ki = 155 ± 4 nM) and that it is a functional CB2 agonist.

5. Key Constituents, Chemistry, and Mechanisms of Action

5.1 Chemical Structure

All terpenoids are formed from the same basic five-carbon isoprene unit and are classified by the number of isoprene units they contain; terpenoids derived from three isoprene units are known as sesquiterpenes, which is the largest group of terpenoids in plants. BCP is thus a sesquiterpene with the molecular formula C₁₅H₂₄. Its hallmark structural features are an unusual 4-membered cyclobutane ring fused to a 9-membered macrocyclic ring containing a trans-configured endocyclic double bond and an exocyclic methylene group — features that are chemically rare in naturally occurring terpenoids. In nature, BCP mainly occurs as trans-caryophyllene mixed with small amounts of its isomers, (Z)-BCP (isocaryophyllene) and α-humulene (α-caryophyllene), as well as its oxidation derivative BCP oxide.

5.2 CB2 Receptor Agonism — The Primary Mechanism

The most thoroughly characterized and pharmacologically consequential mechanism of BCP is selective agonism at the cannabinoid receptor type 2 (CB2R). The psychoactive cannabinoids from Cannabis sativa L. and the arachidonic acid-derived endocannabinoids are nonselective natural ligands for cannabinoid receptor type 1 (CB1) and CB2 receptors. Although the CB1 receptor is responsible for the psychomodulatory effects, activation of the CB2 receptor is a potential therapeutic strategy for the treatment of inflammation, pain, atherosclerosis, and osteoporosis.

BCP is recognized as a full selective functional agonist on CB2 receptors and produces therapeutic effects by activating CB2 and the nuclear receptors, peroxisome proliferator-activated receptors (PPARs). BCP possesses several important pharmacological activities, ranging from pain treatment to neurological and metabolic disorders; these are mainly due to its ability to interact with the cannabinoid receptor 2 (CB2) and the complete lack of interaction with the brain CB1.

Gertsch and colleagues first recognized BCP as a functional CB2R agonist using numerous model systems, including in silico, in vitro, and in vivo studies, and in molecular docking studies, BCP was observed to interact with CB2R on the same binding sites as that of CP55,940, a CB2R agonist.

Because BCP does not bind CB1, CB2R has received attention for its pharmacological effects as antioxidant, anti-inflammatory, immunomodulatory, and antiapoptotic, that can be achieved without causing psychotropic adverse effects through CB1R. This property sets BCP apart from classical phytocannabinoids such as THC.

5.3 NF-κB Pathway Inhibition

BCP showed tissue-protective properties and favorably modulates numerous signaling pathways and inhibits inflammatory mediators, including cytokines, chemokines, adhesion molecules, prostanoids, and eicosanoids. The molecular mechanisms underlying this anti-inflammatory effect appear to involve the control of microglial activity by CB2R, interfering with the NF-κB pathway and mitogen-activated protein kinase (MAPK) pathways [c-Jun N-terminal Kinase (JNK), ERK, or p38]. BCP significantly protected human microglial HMC3 cells from Aβ₂₅₋₃₅-induced cytotoxicity, reducing the release of pro-inflammatory cytokines (TNF-α, IL-6) while enhancing IL-10 secretion; these effects were associated with a reduced activation of the NF-κB pathway, which emerged as a central mediator of BCP action.

5.4 PPAR-γ Activation

β-Caryophyllene modulates the activity of peroxisome proliferator-activated receptors-gamma (PPAR-γ) and inhibits the activation of toll-like receptors (TLRs), thus reducing the immune-inflammatory pathways in the central and peripheral nervous system. The anxiolytic, anti-oxidant, and anti-inflammatory effects of BCP are mediated by both PPAR-γ and CB2R. The interplay between CB2R agonism and PPAR-γ activation is increasingly recognized as a dual mechanism contributing to BCP's metabolic and anti-inflammatory properties.

5.5 Antioxidant and Nrf2 Activation

BCP controls reactive oxygen species (ROS) through multiple pathways; ROS are frequently products and causes of chronic inflammation inciting immune activation and mitochondrial dysfunction. β-Caryophyllene has been shown to protect glioma cells from glutamate-induced cytotoxicity through alteration of antioxidant responses, mainly by inhibition of ROS production via CB2 receptor-dependent nuclear factor erythroid 2–related factor 2 (Nrf2) activation.

5.6 Neuroprotective Signaling

By influencing the PGC-1α and AMPK/CREB signaling pathways, BCP enhances hippocampal BDNF levels while reducing hippocampal COX-2 expression, ultimately promoting neuroprotection. Moreover, BCP restored the expression of SIRT1, PGC-1α, and BDNF, indicating the involvement of neurotrophic pathways. Clear neuroprotective properties for BCP have been highlighted in Aβ₁₋₄₂-treated brain slice preparations, where BCP demonstrated the rescue of both the amyloid-dependent depression of BDNF expression and long-term synaptic potentiation (LTP) impairment.

5.7 Metabolic Pathways

BCP modulates the SIRT1/PGC-1α and PPARγ pathways, leading to decreased LDL and triglyceride levels and increased HDL levels, resulting in improved plasma insulin levels; this modulation also reduces the release of inflammatory agents, contributing to a decrease in overall inflammation. The underlying mechanism of BCP's cholesterol-lowering action is scavenging ROS, leading to deactivation of HMG-CoA reductase and inhibition of endogenous cholesterol synthesis.

6. Scientific Evidence by Area of Use

Important framing note: The overwhelming majority of evidence for BCP's biological activities derives from in vitro cell studies and in vivo animal (primarily rodent) models. As of mid-2025, direct human clinical trial data on isolated, purified BCP are limited. Where human evidence exists, it is typically from studies on BCP-rich plant extracts (particularly copaiba oleoresin) rather than purified BCP, a distinction that limits compound-specific conclusions.

6.1 Inflammation and Pain

Animal and Preclinical Evidence (Strong): The widespread plant volatile BCP was recently identified as a natural selective agonist of the peripherally expressed cannabinoid receptor 2 (CB₂). A number of studies have shown that CB₂ is critically involved in the modulation of inflammatory and neuropathic pain responses. In one study investigating the analgesic effects of BCP in animal models of inflammatory and neuropathic pain, orally administered BCP reduced inflammatory (late phase) pain responses in the formalin test in a CB₂ receptor-dependent manner, while it had no effect on acute (early phase) responses; in a neuropathic pain model, chronic oral administration of BCP attenuated thermal hyperalgesia and mechanical allodynia, and reduced spinal neuroinflammation.

In a study examining sex differences, rats received BCP per os for 7 days at two dosages of 5 and 10 mg/kg dissolved in olive oil in a model of persistent inflammatory pain. The study confirmed CB2 agonism as the key analgesic mechanism.

Human/Clinical Evidence (Emerging, Limited): There are no human studies characterizing the pharmacokinetics of BCP in humans, and it is considered of great importance to determine the pharmacokinetics of BCP in humans so that appropriate dosing can be developed for analgesia. A clinical trial (NCT04794205) was registered at ClinicalTrials.gov to investigate acute thermal pain responses and pharmacokinetics following a single oral dose of BCP in humans, though results were not yet publicly available at the time of this writing.

6.2 Neuroinflammation and Neuroprotection

Preclinical Evidence (Substantial): Literature data suggest that β-caryophyllene, a dietary phytocannabinoid, possesses a neuroprotective capability through decreasing oxidative stress and stabilizing mitochondria, and could be a potential lead molecule in the discovery of drugs for neurodegenerative disorders. Collaborating scientists from Spain and Mexico tested the link between CB2 receptor activation and neuroprotection by β-caryophyllene, involving the exposure of dopaminergic neurons to MPTP, which resulted in inactivation of dopaminergic neurons and microglial activation; treatment of neuronal cells with β-caryophyllene prior to MPTP exposure was found to diminish nervous system inactivation and decrease microglial activation.

Clear neuroprotective properties for BCP have been highlighted in Aβ₁₋₄₂-treated brain slice preparations, where BCP demonstrated the rescue of both the amyloid-dependent depression of BDNF expression and LTP impairment; overall, results suggest that BCP constitutes an attractive natural molecule for the treatment of Aβ-induced neuroinflammation and synaptic dysfunction, warranting further exploration for its clinical application.

Human Evidence: No completed clinical trials in humans on BCP for neurodegenerative disease have been published at the time of this writing. Evidence remains preclinical.

6.3 Anxiety and Depression

Animal Evidence (Substantial, Multiple Models): Recent evidence suggests that the cannabinoid receptor subtype 2 (CB2) is implicated in anxiety and depression disorders. The effects of the CB2 receptor potent-selective agonist β-caryophyllene (BCP) in animals subjected to models of anxiolytic- and antidepressant-like effects have been tested. Effects of BCP (50 mg/kg) on anxiety were assessed using the elevated plus maze, open field, and marble burying tests; for depression, the novelty-suppressed feeding, tail suspension test, and forced swim tests were used. Pre-administration of the CB2 receptor antagonist AM630 fully abrogated the anxiolytic and the anti-depressant effects of BCP, suggesting that CB2 receptors may provide alternative therapeutic targets for the treatment of anxiety and depression.

BCP-evoked antidepressant and memory improvement are likely mediated only via CB2R, mainly by upregulation of PGC-1α and BDNF.

Human Evidence (Absent): Numerous animal studies have demonstrated that BCP has the potential to ameliorate behavioral and inflammatory responses related to chronic and acute stress, suggesting its potential clinical value for the treatment of depression and anxiety. However, it is important to underline that the application of this natural compound in human therapy still requires extensive investigation, and to date, no clinical trials have been conducted to investigate the CB2R-dependent protective mechanisms of BCP on anxiety and depression. The evidence for anxiety and depression is therefore entirely preclinical.

6.4 Metabolic Syndrome, Obesity, and Liver Disease

Preclinical Evidence (Moderate): In preclinical studies, BCP shows beneficial effects on obesity, non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) liver diseases, diabetes, cardiovascular diseases, pain, and other nervous system disorders. One study investigated the effects of (E)-β-caryophyllene on HepG2 steatotic hepatocytes, showing that BCP is able to decrease lipid accumulation in steatotic conditions and to change the typical steatotic lipid profile by primarily reducing saturated fatty acids. BCP was found to modulate key receptors, including FFAR3, LEPR, and GHSR, which are involved in appetite regulation and insulin sensitivity.

Treatment of male Wistar rats with β-caryophyllene ameliorated high fat/fructose diet-induced metabolic and neurobehavioral alterations (insulin resistance, oxidative stress, and neuroinflammation) through activation of PPAR-γ in a ligand-dependent manner.

Human Evidence: No completed clinical trials isolating BCP for metabolic endpoints have been published. Evidence remains preclinical.

6.5 Dermatology and Skin Conditions

Preclinical and Early Human Evidence (Limited): A 2025 systematic review published in Pharmaceuticals specifically addressed this area. Chronic inflammatory skin disorders, including atopic dermatitis, psoriasis, acne, and chronic wounds, affect nearly two billion people worldwide. The cutaneous endocannabinoid system, comprising cannabinoid receptors, regulates inflammation, pruritus, barrier integrity, and tissue repair; cannabinoid receptor type 2 (CB2) has emerged as a particularly relevant target. β-Caryophyllene, a dietary sesquiterpene and highly selective CB2 agonist with favorable safety and pharmacokinetic attributes, has attracted attention as a promising topical candidate.

Human evidence, limited to BCP-rich botanicals such as Copaifera oleoresins, suggests benefits for scars, wounds, and acne but lacks compound-specific validation. BCP exhibits coherent CB2-mediated anti-inflammatory, antipruritic, antioxidant, and reparative actions with a favorable safety profile. Dose-defined, oxidation-controlled clinical trials of purified BCP are warranted to establish its potential as a steroid-sparing topical therapy.

6.6 Addiction and Substance Use Disorders

Preclinical Evidence (Early): Recent research indicates that brain cannabinoid CB2 receptors are involved in drug reward and addiction; however, it is unclear whether β-caryophyllene, a natural product with a CB2 receptor agonist profile, has therapeutic effects on methamphetamine abuse and dependence. Animal self-administration and brain stimulation reward models have been used to explore BCP's effects on methamphetamine-taking and methamphetamine-seeking behavior. Previous research reported that genetic deletion and/or pharmacological blockade of the CB1, GRP55, mu opioid, and TLR4 receptors failed to alter BCP's action on cocaine self-administration, suggesting that these receptors are not involved in BCP's action against cocaine. Unexpectedly, peroxisome proliferator-activated receptor-α (PPARα) or PPARγ antagonists dose-dependently attenuated BCP's action against cocaine self-administration, suggesting PPAR involvement. All evidence is preclinical; no human trials exist.

6.7 Antimicrobial and Antiparasitic Activity

Preclinical Evidence: A PMC-published study (2013) investigated copaiba oil's antileishmanial activity. Sesquiterpene-rich oils and isolated β-caryophyllene presented a dose-dependent activity against intracellular amastigotes, with IC₅₀ values of 2.9 µg/mL, 2.3 µg/mL, and 1.3 µg/mL (6.4 µM), respectively. Evidence for antimicrobial activity is largely in vitro and in preclinical models.

6.8 Cancer Biology

In Vitro Evidence Only: Several in vitro studies have investigated BCP's effects on cancer cell lines. When activated, CB2R inhibits the release of pro-inflammatory mediators by microglia, resulting in a neuroprotective effect in different neuropsychiatric conditions and has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), depression, anxiety, and addiction. Studies on multiple myeloma cells have shown antiproliferative and apoptosis-inducing effects in vitro. All oncological evidence is from cell culture models; no clinical oncology trials of BCP have been conducted.

7. Body Systems Associated with BCP

• Immune system: BCP is regarded as the first dietary cannabinoid with abundant presence across cannabis and non-cannabis plants, including spices and other edible plants. CB2 receptors are highly expressed in immune tissues, and BCP's immunomodulatory effects — reducing pro-inflammatory cytokines and modulating microglial activity — are the most robustly documented.
• Nervous system: Besides CB2 receptor agonism, β-caryophyllene has been found to positively regulate PPAR-γ, TLRs, and neuroimmune pathways. Neuroprotective effects in Alzheimer's and Parkinson's models have been demonstrated preclinically.
• Musculoskeletal / pain system: Analgesic effects in inflammatory and neuropathic pain models are among the most extensively studied effects of BCP in rodents.
• Metabolic/endocrine system: Besides its analgesic effects, BCP influences levels of glucose and cholesterol.
• Gastrointestinal system: Anti-inflammatory effects in colitis models have been demonstrated preclinically.
• Integumentary system (skin): The cutaneous endocannabinoid system regulates inflammation, pruritus, barrier integrity, and tissue repair. Topical BCP has shown preclinical activity in skin inflammation models.

8. Dosage Forms and Dosages Reported in Research

The following dosage information is reported directly as it appears in the cited scientific literature. These are research dosages in animal studies or concentrations used in in vitro experiments; no standardized human therapeutic dose has been established for isolated BCP.

• Rodent oral analgesic studies: Rats received BCP per os for 7 days at two dosages: 5 and 10 mg/kg dissolved in olive oil.
• Rodent anxiety/antidepressant studies: Effects of BCP at 50 mg/kg on anxiety were assessed using the elevated plus maze, open field, and marble burying test.
• Topical concentration range (in vitro and preclinical): Tested concentration ranges for topical applications span from 0.5 µM to 10%.
• Toxicology dose range studied: Toxicity studies by various routes of administration in animals are mainly in rodents, and the currently available toxicological information shows no evidence of neurotoxicity, hepatotoxicity, cardiotoxicity, nephrotoxicity, genotoxicity, or mutagenicity at doses evaluated (30–5,000 mg/kg).
• Repeated-dose tolerance (rodents): Rats given up to 700 mg/kg daily for 90 days did not produce any significant toxic effects.

There are no human studies characterizing pharmacokinetics of BCP in humans, and determining BCP pharmacokinetics in humans is considered essential so that appropriate dosing can be developed for analgesia. Supplement labels for commercial BCP products typically reference doses ranging from 30 mg to 200 mg per day, but these figures are not yet validated by published human pharmacokinetic or clinical efficacy studies.

9. Safety Considerations and Known Interactions

9.1 Regulatory Safety Status

Caryophyllene has been given generally recognized as safe (GRAS) designation by the FDA and is approved by the FDA for use as a food additive, typically for flavoring. β-Caryophyllene is on the list of food additives and flavoring agents approved by the United States Food and Drug Administration (FDA, Code of Federal Regulations No. 21CFR172.515). This GRAS designation pertains to its use as a flavoring substance and does not constitute approval for therapeutic use as a dietary supplement at pharmacological doses.

9.2 Animal Toxicology

Studies related to acute and repeated dose toxicity in rodents of both sexes resulted in the absence of adverse effects, neurotoxicity, hepatotoxicity, nephrotoxicity, genotoxicity, and deaths. Considering that the doses widely used in pharmacological studies hardly exceed 300 mg/kg, which is well below the doses used in toxicological studies, β-caryophyllene can be considered safe when considering rodent, in vitro, and in silico studies. Caryophyllene has an LD₅₀ of 5,000 mg/kg in mice.

9.3 Autoxidation and Contact Sensitization

A pharmacologically and practically important safety consideration is BCP's susceptibility to air oxidation. β-Caryophyllene starts to oxidize immediately when air-exposed, and after 5 weeks almost 50% of the original compound is consumed; caryophyllene oxide is the major oxidation product. Caryophyllene oxide was shown to be an allergen of moderate strength, and β-caryophyllene air-exposed for 10 weeks showed a weak sensitizing capacity in the local lymph node assay. However, the allergenic activity of β-caryophyllene is affected by autoxidation but to a lesser extent when compared to R-limonene and linalool, and clinical studies have shown oxidized β-caryophyllene to be a rather rare sensitizer compared to oxidized R-limonene and linalool.

BCP is volatile and prone to autoxidation, yielding products such as caryophyllene oxide (BCPO) that alter pharmacodynamic properties and may increase the risk of sensitization. This has practical implications for both topical formulations and aromatherapy applications: products stored in air-exposed conditions over extended periods may have altered pharmacological profiles and a modestly elevated risk of contact sensitization.

9.4 Absence of Psychotropic Effects

Because BCP binds selectively to CB2 and not to CB1 receptors, its pharmacological activities, ranging from pain treatment to neurological and metabolic disorders, are mainly due to its ability to interact with CB2 and rely on the complete lack of interaction with the brain CB1. BCP does not produce the intoxicating or psychoactive effects associated with CB1 agonists such as THC.

9.5 Known Interactions and Gap in Human Data

Little research has addressed toxicological parameters for BCP specifically in humans. The pharmacological interaction profile with medications remains incompletely characterized. BCP's activity on PPAR-γ receptors — shared with certain thiazolidinedione antidiabetic drugs — represents a theoretically relevant interaction pathway that has not been studied in humans. PPARα and PPARγ antagonists have been shown to dose-dependently attenuate BCP's action in preclinical models, suggesting that PPAR pathways are integral to BCP's mechanism. Whether this translates to meaningful interactions with PPAR-targeting medications in humans is unknown.

9.6 Limitations of the Current Evidence Base

The field is currently characterized by a wide gap between preclinical promise and validated human data. Key outstanding issues include: the absence of well-characterized human pharmacokinetic data for oral BCP; the absence of randomized controlled trials of isolated BCP for any indication; the fact that most human data come from studies using whole plant extracts (especially copaiba oleoresin) rather than purified BCP, making it impossible to attribute outcomes to BCP specifically; and the need for well-designed, oxidation-controlled topical studies with purified BCP. The application of this natural compound in human therapy still requires extensive investigation, and to date, no clinical trials have been conducted to investigate the CB2R-dependent protective mechanisms of BCP on anxiety and depression.

References

• Gertsch J et al. (2008). Beta-caryophyllene is a dietary cannabinoid. PNAS 105(26):9099–9104.
• Maffei ME (2020). Plant Natural Sources of the Endocannabinoid (E)-β-Caryophyllene: A Systematic Quantitative Analysis of Published Literature. Int J Mol Sci 21(18):6540. PMC7554841.
• Sharma C et al. (2021). A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of β-caryophyllene, a dietary cannabinoid. Biomed Pharmacother 140:111639.
• Klauke AL et al. (2014). The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol 24(4):608–620.
• Bahi A et al. (2014). β-Caryophyllene, a CB2 receptor agonist, produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol Behav 135:119–124.
• Negrete R et al. (2020). The CB2 Agonist β-Caryophyllene in Male and Female Rats Exposed to a Model of Persistent Inflammatory Pain. Front Neurosci 14:850. PMC7461959.
• Gallo M et al. (2024). Beta-Caryophyllene, a Cannabinoid Receptor Type 2 Selective Agonist, in Emotional and Cognitive Disorders. Int J Mol Sci 25(5):2940. PMC10970213.
• Ghasemzadeh Rahbardar M, Hosseinzadeh H (2021). Improvement of Oxidative Stress and Mitochondrial Dysfunction by β-Caryophyllene: A Focus on the Nervous System. Naunyn Schmiedebergs Arch Pharmacol. PMC8066981.
• Multi-Target Protective Effects of β-Caryophyllene (BCP) at the Intersection of Neuroinflammation and Neurodegeneration (2025). Int J Mol Sci. PMC12249661.
• Bagher AM (2025). Topical β-Caryophyllene for Dermatologic Disorders: Mechanisms, Human Evidence, and Clinical Translation. Pharmaceuticals 18(11):1605. PMC12655451.
• Aly E et al. (2021). β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19. Front Pharmacol 12:590201.
• Galaj E et al. (2021). β-Caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms. Front Pharmacol 12:722476.
• ScienceDirect Topics: Caryophyllene — overview of pharmacology and CB2 agonism.
• Dias DA et al. (2018). Copaifera of the Neotropics: A Review of the Phytochemistry and Pharmacology. Int J Mol Sci 19(5):1511. PMC5983702.
• Evaluation of the biological activities of Copaiba (Copaifera spp): a comprehensive review based on scientometric analysis. PMC10502340.
• Soares DC et al. (2013). Trans-β-Caryophyllene: An Effective Antileishmanial Compound Found in Commercial Copaiba Oil. PMC3705974.
• Sköld M et al. (2006). The fragrance chemical β-caryophyllene — air oxidation and skin sensitization. Food Chem Toxicol 44(4):538–545.
• Safety and toxicology of the dietary cannabinoid β-caryophyllene. ScienceDirect Book Chapter, 2023.
• Caryophyllene — Wikipedia (for structural, GRAS, and LD₅₀ data cross-reference).
• ClinicalTrials.gov NCT04794205: Acute Changes In Thermal Pain Response Following Single Oral Dose of Beta-Caryophyllene.
• Effect of β-Caryophyllene on PPAR-γ, NF-κB, and CNR2: Implications for Gut–Brain Axis Communication in a Murine Model of Diet-Induced Obesity. Metabolites 2025;15(10):638.
• Muthusamy S et al. (2020). Transient expression and purification of β-caryophyllene synthase in Nicotiana benthamiana to produce β-caryophyllene in vitro. PeerJ 8:e8904. PMC7194099.